CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 206,265	$ 103,193
Accounts receivable	250	523
Prepaid expenses	10,738	8,913
Other current assets	2,248	3,046
Total current assets	219,501	115,675
Property, equipment, and software—net	38,959	21,147
Intangible assets—net	1,446	1,466
Other assets	392	312
Total assets	260,298	138,600
Current liabilities:
Accounts payable	4,465	2,218
Accrued compensation	2,961	965
Accrued clinical and research and development expenses	3,556	1,569
Accrued other expenses and other current liabilities	1,977	887
Deferred revenue	10,767	8,436
Total current liabilities	23,726	14,075
Deferred revenue—noncurrent	77,887	82,807
Deferred rent—noncurrent	2,897	1,758
Total liabilities	104,510	98,640
Commitments and contingencies (Note 4)
Stockholders’ equity:
Preferred stock
Additional paid-in capital	312,891	126,094
Accumulated deficit	(156,151)	(85,187)
Treasury stock	(952)	(952)
Total stockholders’ equity	155,788	39,960
Total liabilities and stockholders’ equity	$ 260,298	138,600
Series A Convertible Preferred Stock
Stockholders’ equity:
Preferred stock		3
Total stockholders’ equity		3
Series B Convertible Preferred Stock
Stockholders’ equity:
Preferred stock		2
Total stockholders’ equity		$ 2

Accrued clinical and research and development expenses.

No definition available.

Name:	dtil_AccruedClinicalAndResearchAndDevelopmentExpenses
Namespace Prefix:	dtil_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).